Australian Rheumatology Association Database  

What is ARAD?

  • It is a national Australian database which collects important health information from individuals with inflammatory arthritis such as:

Rheumatoid arthritis
Ankylosing spondylitis
Juvenile arthritis
Psoriatic arthritis

  • The aim of ARAD is to determine effectiveness and safety of new biological drugs used to treat inflammatory arthritis condition, such as Enbrel, Remicade, Humira, Kineret, MabThera and Orencia.
  • ARAD collects information from patients every 6 months via questionnaires. Questions about medical history, medication history, responses to medication, physical functioning and quality of life are included.
  • Patients and rheumatologists across Australia contribute to ARAD.
Further details in the Participant Brochure

The benefits of participating in and supporting ARAD

  • ARAD provides a valuable resource for all patients with this chronic disease and their clinicians by monitoring individual patient outcomes and adverse events.
  • Annual reports are provided to participating rheumatologists with the progress of their own patients as well as comparing their patients to the ARAD population.
  • Information on the ARAD population is provided to participants, clinicians, researchers and policy makers. This is combined information only and contains nothing that would allow an individual to be identified.
  • Regular newsletters are provided to participants updating them with information about ARAD. Click here for all newsletters.
Currently funded by: Unrestricted educational grants from Pfizer Pty Ltd, Bristol-Myes Squibb Pty Ltd and AbbVie Pty Ltd administered through the ARA

Supported by:
Monash University
Cabrini Health

with additional funding through Educational Grants to the ARA from:
Abbott Australasia Pty Ltd
Pfizer Pty Ltd

previous educational grants were provided to the ARA by:
Amgen Australia Pty Ltd
Roche Products Pty Ltd
Monash University
Cabrini Healt

Click for easy access: